Goodbody Health Limited
GDBYF · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 7/31/2018 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 755.5% | 37.6% | 220.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 52.4% | 56.4% | 52% | 0% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -6.2% | -224% | -229.1% | -38.9% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -13.6% | -233.7% | -262.1% | -77.1% |
| EPS | -0.067 | -0.29 | -0.48 | -0.17 |
| % Growth | 76.9% | 39.6% | -182.4% | – |
| EPS Diluted | -0.067 | -0.29 | -0.48 | -0.17 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -0.1% | -206.6% | -227.3% | -38.7% |